Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIVASTIGMINE vs ROLAPITANT: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIVASTIGMINE vs ROLAPITANT: Safety Overview

Metric RIVASTIGMINE ROLAPITANT
Total FAERS Reports 9,123 873
Deaths Reported 2,232 252
Death Rate 24.5% 28.9%
Hospitalizations 2,716 155
Average Patient Age 80.0 yrs 61.4 yrs
% Female Patients 59.5% 57.5%
FDA Approval Date Apr 21, 2000 Oct 25, 2017
Manufacturer Novartis Pharmaceuticals Corporation TerSera Therapeutics LLC
Route TRANSDERMAL ORAL
Marketing Status Discontinued Prescription